Annexin A2 (ANXA2) gene variants and ischemic stroke risk
Genetic Variants of Annexin A2 and Cryptogenic Stroke
This project will test whether genetic differences in the annexin A2 (ANXA2) gene are linked to ischemic stroke in adults who have already experienced a completed ischemic stroke.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 240 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Locations | 1 site (Amiens) |
| Trial ID | NCT06880107 on ClinicalTrials.gov |
What this trial studies
Researchers will enroll adults with a completed ischemic stroke and collect a blood sample for DNA analysis. The DNA will be genotyped to identify single nucleotide variants in the ANXA2 gene and related loci. Genotype frequencies will be compared with expected population patterns or correlated with clinical stroke features to see if specific variants are overrepresented. The work is conducted at CHRU Amiens and excludes transient ischemic attack and pregnant participants.
Who should consider this trial
Good fit: Adults aged 18 or older who have had a completed ischemic stroke (neurologic deficit persisting beyond 24 hours) and can provide a blood sample are the ideal candidates.
Not a fit: People whose event was a transient ischemic attack, who are pregnant, or whose stroke has an already identified non-genetic cause are unlikely to benefit from this genetic analysis.
Why it matters
Potential benefit: If successful, identifying ANXA2 variants linked to stroke could help spot people at higher genetic risk and suggest new targets to improve fibrinolytic treatment.
How similar studies have performed: Previous human studies have linked other fibrinolysis-related genes (tPA, PAI-1) to stroke risk and animal work shows recombinant ANXA2 can aid fibrinolysis, but human data specifically linking ANXA2 variants to typical ischemic stroke remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Completed ischemic stroke defined as a rapidly developing focal neurologic deficit with no apparent cause other than a vascular origin that persisted beyond 24 hours in surviving patients * Age from 18 years old Exclusion Criteria: * Transient ischemic attack * Pregnancy
Where this trial is running
Amiens
- CHRU Amiens — Amiens, France (Recruiting)
Study contacts
- Study coordinator: Valéry SALLE, MD
- Email: salle.valery@chu-amiens.fr
- Phone: 33+3 22 66 82 30
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.